News
Takeda revealed a handful of pipeline cuts in its fourth-quarter earnings results on Thursday, as the company focuses its ...
AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...
Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...
The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease ...
'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis
Fyodor Urnov and Kiran Musunuru advocate for streamlined CRISPR treatments for rare genetic diseases, partnering with Danaher ...
Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...
Lantheus finally came clean about the fate of its experimental radiopharmaceutical for prostate cancer, ...
A federal court handed the FDA and Eli Lilly a major win in a case challenging the end of the tirzepatide shortage.
President Trump met with pharma CEOs at the White House. After praising investments, a 'most favored nation' drug pricing ...
Charles River Laboratories is set to start a strategic review and add four new board members after it settled on a ...
The FDA announced a two-day meeting of its Oncologic Drugs Advisory Committee (ODAC) later this month to review cancer drugs ...
CRISPR Therapeutics has revealed promising but early data from its first clinical study of a gene editing therapy to lower ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results